New Canine Cancer Therapy Shows Promise in First-in-Dog Studies

CORVALLIS, Ore. & MEDFORD, Mass. – April 14, 2026 – In a development offering a new ray of hope for millions of pet owners, biotechnology firm BioTesserae Inc. today announced that its novel canine cancer therapy, BTC-001, was successfully tolerated in its first-in-dog clinical study. The milestone, achieved in collaboration with manufacturing partner Sunflower Therapeutics PBC, marks a critical step toward bringing a new class of immunotherapy—inspired by successful human cancer treatments—to the veterinary market, with a key focus on affordability and accessibility.

BTC-001 is a single domain antibody (SdA) designed to inhibit the PD-1 immune checkpoint, effectively unleashing a dog’s own immune system to fight cancer cells. The positive safety results from this initial trial could signal a coming shift in how veterinarians and families confront one of the most devastating diseases in companion animals.

A New Front in the Battle Against Canine Cancer

For dog owners, a cancer diagnosis is a heartbreaking and often financially crippling event. Cancer is a leading cause of death in all dog breeds, with an estimated six million new cases diagnosed in dogs and cats each year in the United States alone. The path to treatment is frequently fraught with difficult choices and significant expense.

Standard care—including surgery, radiation, and chemotherapy—can be effective but comes at a steep price. A full course of chemotherapy can range from $3,000 to over $10,000, depending on the drug protocol and the size of the dog. Radiation and complex surgeries can add thousands more to the bill, placing effective treatment out of reach for many families. The global pet cancer therapeutics market, currently valued at over $400 million, is projected to more than double by 2034, underscoring the urgent need for more effective and economical options.

BioTesserae’s BTC-001 enters this landscape as a promising alternative. By targeting the PD-1 pathway, it mimics the mechanism of blockbuster human immunotherapy drugs like Keytruda and Opdivo, which have revolutionized human oncology. The initial study demonstrated that BTC-001 was well tolerated in healthy dogs, even at doses three times higher than the anticipated therapeutic level. While the company did not release detailed adverse event data, a “well tolerated” profile in early-stage veterinary trials typically indicates the absence of serious side effects, a crucial hurdle for any new drug.

“This study addresses two key milestones for BioTesserae,” said Dr. Patrick Iversen, CEO of BioTesserae Inc., in a statement. “First, we demonstrated that the proprietary single domain antibody to PD-1 (BTC-001) is well tolerated in dogs following a single dose up to three times the anticipated therapeutic dose. Second, we accomplished the synthesis, purification, concentration, and release of the single domain antibody in yeast at pilot scale.”

The Science of Simplicity and Affordability

The innovation behind BTC-001 is twofold, involving both the drug’s design and its manufacturing process. The therapy is built on a single domain antibody (SdA) platform. Unlike conventional monoclonal antibodies, SdAs are smaller and structurally simpler, which can make them easier and more cost-effective to produce and potentially less likely to cause an immune reaction in the patient.

This inherent simplicity is a perfect match for the groundbreaking manufacturing technology provided by Sunflower Therapeutics. The public benefit corporation is pioneering the use of an engineered yeast-based platform to produce complex biologic drugs. This method stands in stark contrast to the industry standard of using mammalian cell cultures, which are notoriously expensive and complex to maintain.

Yeast systems offer numerous advantages: they grow rapidly, thrive in inexpensive nutrient media, and can be scaled up efficiently in large fermenters. Furthermore, as a eukaryotic organism, yeast can perform the complex protein folding and modifications required for biologic drugs to function correctly—a key advantage over even simpler bacterial systems. This efficiency is the foundation of the collaborators' claim that they can deliver a sophisticated immunotherapy at a more affordable price point.

“Through the completion of this study, we have shown how our engineered yeast host and a product optimization approach centered on manufacturability-by-design can enable the production of novel high-quality protein-based veterinary therapies in meaningful quantities for clinical and commercial development,” stated Dr. Laura Crowell Orella, Director of R&D at Sunflower Therapeutics. “In partnership with BioTesserae, we are achieving significant milestones in the development of affordable solutions for canine cancer.”

A Disruptive Model With Global Ambitions

The collaboration’s impact may extend far beyond the veterinary clinic. Sunflower Therapeutics operates with a broader mission to democratize bioprocessing and make essential protein-based products accessible worldwide. As a women-led public benefit corporation, its goal is to dismantle the high-cost, centralized manufacturing paradigm that dominates the pharmaceutical industry.

By developing modular, automated, and fully-integrated manufacturing solutions, Sunflower aims to empower companies of all sizes to produce biologics where they are needed most. This technology has already attracted attention from the U.S. Department of Defense for its potential to create “Biologics on Demand” for rapid medical countermeasure production. The success with BTC-001 serves as a powerful proof-of-concept for this disruptive model, showing it can be applied to create affordable vaccines, therapeutics, and other vital products for both human and animal health, particularly in low- and middle-income regions.

The road ahead for BTC-001 will involve more extensive trials to prove its effectiveness in dogs diagnosed with cancer. However, this initial safety milestone, combined with the validation of a revolutionary manufacturing process, represents a significant convergence of comparative oncology and bioprocessing innovation. It is a scientific and industrial partnership that brings the promise of advanced, life-extending cancer care one step closer to becoming an accessible reality for the pets that are integral members of our families.